NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

Rhea-AI Summary

NiKang Therapeutics has formed a clinical trial collaboration with Pfizer (PFE) to evaluate NKT2152, targeting advanced clear cell renal cell carcinoma (ccRCC). The trial will assess NKT2152 in combination with Pfizer’s palbociclib and sasanlimab for patients unresponsive to prior treatments. NiKang will sponsor the study while Pfizer co-funds it and supplies drugs at no cost. The collaboration aims to leverage complementary pathways for effective therapy. Currently, NKT2152 is in a phase 1/2 trial to determine safety and efficacy.

Positive

• Collaboration with Pfizer enhances trial resources and expertise.
• NKT2152 targets ccRCC, addressing unmet medical needs.
• Pfizer co-funds and provides drugs at no cost, reducing financial burden.

Negative

• None.

WILMINGTON, Del.--(BUSINESS WIRE)-- NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (NYSE: PFE) to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with palbociclib, a CDK4/6 inhibitor, and sasanlimab, a subcutaneously administered PD-1 inhibitor for the treatment of advanced clear cell renal cell carcinoma (ccRCC). It will comprise two different combination regimens to treat ccRCC patients who have not responded to or relapsed from prior therapies. Under the terms of the agreement, NiKang will sponsor the study, and Pfizer will co-fund the trials and provide its drugs at no cost to NiKang. The two companies will form a Joint Development Committee to oversee this collaboration.

“We are excited to work with Pfizer, a company that has been a leader in RCC drug development for nearly two decades, and appreciate its recognition of the potential for these important combination strategies in helping ccRCC patients in need. The scientific rationale of these novel combinations is compelling as they target different and complementary pathways,” said Zhenhai Gao, Ph.D., co-founder, president, and CEO of NiKang. “This clinical collaboration provides an excellent framework under which both companies pool their proprietary products and resources together to effectively explore the potential of these combination therapies.”

NKT2152 is currently in a phase 1/2 dose escalation and expansion trial (NCT05119335). It is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity in patients with advanced ccRCC. Once an appropriate dose is identified, combination studies including NKT2152 and Pfizer’s palbociclib and sasanlimab will commence.

About NiKang Therapeutics

NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Our target selection is driven by deep insights into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design. The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. We strive to bring transformative medicines to patients in need.

For more information, please visit http://www.nikangtx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005397/en/

Kelsey Chen

Chief Financial Officer

IR@nikangtx.com

Source: NiKang Therapeutics Inc.

FAQ

What is the purpose of the NKT2152 clinical trial with Pfizer (PFE)?

The trial aims to evaluate the efficacy of NKT2152 in combination with palbociclib and sasanlimab for treating advanced clear cell renal cell carcinoma (ccRCC).

What phase is the NKT2152 trial currently in?

NKT2152 is currently in a phase 1/2 dose escalation and expansion trial.

When will combination studies involving NKT2152 and Pfizer's drugs begin?

Combination studies will commence once an appropriate dose of NKT2152 is identified.

What is NiKang Therapeutics' focus area?

NiKang Therapeutics focuses on developing innovative small molecule oncology medicines for patients with unmet medical needs.